The ASCO Post Podcast

Latest Episodes:

First FDA Approval for Neoadjuvant Therapy for Early-Stage Non–Small Cell Lung Cancer Mar 11, 2022

Show notes

In this week’s episode, we’ll discuss a recent U.S. Food and Drug Administration (FDA) approval in the early-stage non–small cell lung cancer setting. Then, we’ll hear about a study presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium that investigated methods for the de-escalation of radiation therapy for oropharyngeal cancer.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Neoadjuvant Nivolumab and Platinum Doublet Chemotherapy for Early-Stage NSCLC

Midtreatment Imaging De-escalates Therapy for Half of Patients With Oropharyngeal Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Reports From the 2022 Multidisciplinary Head and Neck Cancers Symposium Mar 04, 2022

Show notes

The 2022 Multidisciplinary Head and Neck Cancers Symposium took place from February 24 to 26 in Phoenix, Arizona. The meeting provided the most up-to-date information on multidisciplinary therapies, clinical research, treatment strategies, supportive care, and scientific breakthroughs in head and neck cancer. On this episode of the podcast, we’ll hear from three authors who presented their research at the meeting.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

More From the ASCO Genitourinary Cancers Symposium: Data on Bladder Cancer, Prostate Cancer, and Treatment Disparities Mar 01, 2022

Show notes

In this episode, we’re highlighting three presentations from the ASCO Genitourinary Cancers Symposium, held recently in San Francisco.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

News From the 2022 ASCO Genitourinary Cancers Symposium Feb 18, 2022

Show notes

The 2022 ASCO Genitourinary Cancers Symposium kicked off this week. On this episode, we’ll hear about two studies presented at the meeting: one, focused on a genetic risk score that may aid in identifying men with high vs low lifetime risks of developing metastatic prostate cancer or dying from prostate cancer; and the second, about a trial that tested the efficacy of combination immunotherapy and tyrosine kinase inhibitor therapy for renal cell carcinoma.

Coverage of stories discussed this week on ascopost.com:

Comprehensive Genetic Risk Score May Predict Risk of Developing Metastatic Prostate Cancer or Death From Prostate Cancer Across Diverse Populations

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Efficacy of Adagrasib in Various Gastrointestinal Cancers Feb 11, 2022

Show notes

In this episode, we’ll review a report on the KRYSTAL-1 trial of adagrasib therapy in various gastrointestinal cancers, and highlight key points from the newly released AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care.

Coverage of stories discussed this week on ascopost.com:

KRYSTAL-1: Adagrasib Controls Disease in Gastrointestinal Malignancies Beyond Colorectal Cancer

AACR Releases Report on the Impact of COVID-19 on Cancer Research and Patient Care

To listen to more podcasts from ASCO, visit asco.org/podcasts.

President Biden Relaunches the Cancer Moonshot Feb 04, 2022

Show notes

This week, we're reviewing a statement issued by the White House earlier this week on the Cancer Moonshot initiative.

Coverage of stories discussed this week on ascopost.com:

President Biden Reignites Cancer Moonshot

To listen to more podcasts from ASCO, visit asco.org/podcasts.

FDA Approval in Metastatic Uveal Melanoma Jan 28, 2022

Show notes

On this episode, we’ll be talking about an FDA approval for uveal melanoma, as well as the efficacy of PD-1 inhibition in patients with resectable liver cancer.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Tebentafusp-tebn for the Treatment of Unresectable or Metastatic Uveal Melanoma

Neoadjuvant Cemiplimab-rwlc for Patients With Resectable Hepatocellular Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Highlighted Presentations From the 2022 ASCO Gastrointestinal Cancers Symposium Jan 24, 2022

Show notes

The 2022 ASCO Gastrointestinal Cancers Symposium took place in San Francisco from January 20 to 22. This week, we’re featuring commentary from the authors involved in two high-impact studies in hepatobiliary cancers.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Relatlimab Plus Nivolumab Improves PFS in Patients With Previously Untreated Metastatic or Unresectable Melanoma Jan 14, 2022

Show notes

On this episode, we’ll hear about a combination therapy that improved progression-free survival in previously untreated patients with melanoma. Then, we’ll hear about a report that looked into the effects of prior radiotherapy on the development of adverse events in patients treated with immune checkpoint inhibitors.

Coverage of stories discussed this week on ascopost.com:

Addition of Anti–LAG-3 Antibody Relatlimab to Nivolumab in Previously Untreated Patients With Advanced Melanoma

Effect of Recent Prior Radiotherapy on Adverse Events in Patients Receiving Immune Checkpoint Inhibitors

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Apatinib for Advanced Radioactive Iodine–Refractory Differentiated Thyroid Cancer Jan 07, 2022

Show notes

On this episode, we’re discussing a phase III trial that showed improved progression-free survival with VEGFR2 inhibition in certain patients with thyroid cancer. Then, we’ll hear about a report on outcomes of breakthrough COVID-19 infection among fully vaccinated patients with cancer.

Coverage of stories discussed this week on ascopost.com:

Apatinib for Advanced Radioactive Iodine–Refractory Differentiated Thyroid Cancer

Study Finds Fully Vaccinated Patients With Cancer and Breakthrough COVID-19 Infection Remain at High Risk for Severe Outcomes

To listen to more podcasts from ASCO, visit asco.org/podcasts.